| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2006PNAS..10316296Z |
| P356 | DOI | 10.1073/PNAS.0607899103 |
| P932 | PMC publication ID | 1637576 |
| P698 | PubMed publication ID | 17060635 |
| P5875 | ResearchGate publication ID | 6734729 |
| P2093 | author name string | Li Wang | |
| Jean J Zhao | |||
| Shidong Jia | |||
| Thomas M Roberts | |||
| Ole V Gjoerup | |||
| Aki Mikami | |||
| Hailing Cheng | |||
| P2860 | cites work | p110δ, a novel phosphoinositide 3-kinase in leukocytes | Q24314825 |
| p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes | Q24319291 | ||
| A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling | Q24599676 | ||
| EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy | Q27824812 | ||
| Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic | Q27824826 | ||
| Synthesis and function of 3-phosphorylated inositol lipids | Q28200755 | ||
| A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation | Q28202234 | ||
| Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice | Q28215433 | ||
| Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras | Q28238120 | ||
| Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes | Q28265486 | ||
| Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways | Q28274882 | ||
| Essential role for the p110delta phosphoinositide 3-kinase in the allergic response | Q28288981 | ||
| Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase | Q28512805 | ||
| Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation | Q28594707 | ||
| Phosphoinositide kinases | Q29618047 | ||
| Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice | Q33860786 | ||
| ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines | Q33928631 | ||
| Essential role of insulin receptor substrate 1 (IRS-1) and IRS-2 in adipocyte differentiation | Q33967843 | ||
| The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells | Q34234737 | ||
| Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. | Q34443608 | ||
| Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. | Q34560078 | ||
| Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. | Q35965439 | ||
| Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase | Q38326223 | ||
| A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma | Q40280414 | ||
| Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action | Q42523855 | ||
| Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. | Q42811529 | ||
| Mechanisms and implications of phosphoinositide 3-kinase delta in promoting neutrophil trafficking into inflamed tissue. | Q44748761 | ||
| The PIK3CA gene is mutated with high frequency in human breast cancers. | Q53366750 | ||
| P433 | issue | 44 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 16296-16300 | |
| P577 | publication date | 2006-10-23 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation | |
| P478 | volume | 103 |
| Q36139665 | A PI3K p110β-Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis |
| Q47565435 | A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer. |
| Q38134714 | AKT-independent PI3-K signaling in cancer - emerging role for SGK3. |
| Q21142629 | Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation |
| Q39656146 | Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma. |
| Q33952917 | Activity of any class IA PI3K isoform can sustain cell proliferation and survival. |
| Q36580450 | Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice. |
| Q38745816 | Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer |
| Q24307014 | B55β-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer |
| Q24307524 | Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice |
| Q38672092 | CRKL Mediates p110β-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells |
| Q38981868 | Cell activation-induced phosphoinositide 3-kinase alpha/beta dimerization regulates PTEN activity |
| Q35808718 | Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers |
| Q34508976 | Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment |
| Q38459968 | Crossroads of PI3K and Rac pathways. |
| Q36703783 | Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer |
| Q33852403 | Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway |
| Q60933000 | Disruption of the Interaction of RAS with PI 3-Kinase Induces Regression of EGFR-Mutant-Driven Lung Cancer |
| Q43106693 | ECRG4 inhibits growth and invasiveness of squamous cell carcinoma of the head and neck in vitro and in vivo |
| Q47617045 | EGFR signalling controls cellular fate and pancreatic organogenesis by regulating apicobasal polarity. |
| Q38637153 | ErbB2-positive mammary tumors can escape PI3K-p110α loss through downregulation of the Pten tumor suppressor |
| Q37360125 | Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis |
| Q33403197 | Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation. |
| Q42441155 | Extended treatment with selective phosphatidylinositol 3-kinase and mTOR inhibitors has effects on metabolism, growth, behaviour and bone strength |
| Q33415058 | Glutamine deprivation induces abortive s-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts |
| Q37679937 | Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α. |
| Q55513184 | Hepatic deletion of p110α and p85α results in insulin resistance despite sustained IRS1-associated phosphatidylinositol kinase activity. |
| Q34452767 | Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K |
| Q48821723 | High frequency of mutations in the PIK3CA gene helical and kinase coding regions in a group of Iranian patients with high-grade glioblastomas: five novel mutations |
| Q36105608 | IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias |
| Q36262959 | Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design |
| Q37602377 | Inhibiting PI3K as a therapeutic strategy against cancer |
| Q38852858 | Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms |
| Q39094806 | Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis |
| Q36892083 | Interleukin 17A inhibits autophagy through activation of PIK3CA to interrupt the GSK3B-mediated degradation of BCL2 in lung epithelial cells |
| Q34406302 | K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo |
| Q64063915 | LMP1 and 2A Induce the Expression of Nrf2 Through Akt Signaling Pathway in Epstein-Barr Virus-Transformed B Cells |
| Q37330814 | Lessons from polyoma middle T antigen on signaling and transformation: A DNA tumor virus contribution to the war on cancer |
| Q35000523 | Lessons in signaling and tumorigenesis from polyomavirus middle T antigen |
| Q36771317 | Long-term p110α PI3K inactivation exerts a beneficial effect on metabolism |
| Q35834882 | MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism That Mimics the Role of Activated RAS in Malignancy |
| Q36557786 | Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer |
| Q45329468 | Modulation of telomere protection by the PI3K/AKT pathway |
| Q54117873 | Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases. |
| Q37968309 | Multiple roles for the p85α isoform in the regulation and function of PI3K signalling and receptor trafficking |
| Q38392667 | Natural course and biology of CML. |
| Q36023300 | PERK utilizes intrinsic lipid kinase activity to generate phosphatidic acid, mediate Akt activation, and promote adipocyte differentiation |
| Q92240330 | PI3 kinase alpha and delta promote hematopoietic stem cell activation |
| Q35260766 | PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting |
| Q30360152 | PI3K in the ventromedial hypothalamic nucleus mediates estrogenic actions on energy expenditure in female mice |
| Q89459605 | PI3K inhibitors in thrombosis and cardiovascular disease |
| Q33674643 | PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context |
| Q36928732 | PI3K p110β subunit in leptin receptor expressing cells is required for the acute hypophagia induced by endotoxemia. |
| Q37039348 | PI3K signaling in glioma--animal models and therapeutic challenges |
| Q41957703 | PI3K signaling in the ventromedial hypothalamic nucleus is required for normal energy homeostasis |
| Q36840275 | PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers |
| Q39023175 | PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment |
| Q28383083 | PI3K/PTEN signaling in angiogenesis and tumorigenesis |
| Q35575601 | PI3K/mTOR signaling regulates prostatic branching morphogenesis |
| Q47894525 | PI3K: A Crucial Piece in the RAS Signaling Puzzle |
| Q47275685 | PI3Kα inactivation in leptin receptor cells increases leptin sensitivity but disrupts growth and reproduction. |
| Q33610437 | PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer |
| Q33991672 | Period 2 is essential to maintain early endothelial progenitor cell function in vitro and angiogenesis after myocardial infarction in mice |
| Q37418266 | Phosphatidyl inositol 3-kinase signaling in hypothalamic proopiomelanocortin neurons contributes to the regulation of glucose homeostasis |
| Q35606261 | Phosphatidylinositol-3-kinase as a therapeutic target in melanoma |
| Q54977577 | Phosphoinositide 3-Kinase Is Integral for the Acute Activity of Leptin and Insulin in Male Arcuate NPY/AgRP Neurons. |
| Q33832537 | Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits |
| Q35550765 | Phosphoinositide 3-kinase signaling pathway mediated by p110α regulates invadopodia formation |
| Q36093388 | Phosphoinositide-3-kinase, catalytic, alpha polypeptide RNA interference inhibits growth of colon cancer cell SW948. |
| Q47551725 | Pik3ca is required for mouse uterine gland development and pregnancy |
| Q37872280 | Progress in the design and development of phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of chronic diseases |
| Q59805226 | Quantitation of class IA PI3Ks in mice reveals p110-free-p85s and isoform-selective subunit associations and recruitment to receptors |
| Q34202692 | RAS Interaction with PI3K: More Than Just Another Effector Pathway |
| Q33289438 | RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms |
| Q38977239 | RAS interaction with PI3K p110α is required for tumor-induced angiogenesis. |
| Q37309754 | Rac1-mediated membrane raft localization of PI3K/p110β is required for its activation by GPCRs or PTEN loss |
| Q37303694 | Requirement for interaction of PI3-kinase p110α with RAS in lung tumor maintenance |
| Q38614205 | Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer |
| Q35994228 | Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma |
| Q35165157 | Role of phosphoinositide 3-OH kinase p110β in skeletal myogenesis |
| Q40989146 | Selective Sparing of Human Tregs by Pharmacologic Inhibitors of the Phosphatidylinositol 3-Kinase and MEK Pathways |
| Q24308859 | Shepherding AKT and androgen receptor by Ack1 tyrosine kinase |
| Q24309044 | Should individual PI3 kinase isoforms be targeted in cancer? |
| Q28283677 | Signaling by the phosphoinositide 3-kinase family in immune cells |
| Q37215752 | Signaling via class IA Phosphoinositide 3-kinases (PI3K) in human, breast-derived cell lines |
| Q50611919 | Silencing of type Iγ phosphatidylinositol phosphate kinase suppresses ovarian cancer cell proliferation, migration and invasion. |
| Q37064604 | Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome |
| Q35131032 | Specific roles of the p110alpha isoform of phosphatidylinsositol 3-kinase in hepatic insulin signaling and metabolic regulation |
| Q90581562 | Structural Perturbations due to Mutation (H1047R) in Phosphoinositide-3-kinase (PI3Kα) and Its Involvement in Oncogenesis: An in Silico Insight |
| Q34632966 | Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. |
| Q29615809 | Targeting the phosphoinositide 3-kinase pathway in cancer |
| Q36305147 | The ERα-PI3K Cascade in Proopiomelanocortin Progenitor Neurons Regulates Feeding and Glucose Balance in Female Mice. |
| Q38341764 | The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development. |
| Q37810478 | The PI3K signaling pathway mediates the biological effects of leptin |
| Q35870445 | The acute effects of leptin require PI3K signaling in the hypothalamic ventral premammillary nucleus |
| Q34317015 | The class IA phosphatidylinositol 3-kinase p110-β subunit is a positive regulator of autophagy |
| Q39958777 | The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression |
| Q37521382 | The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome |
| Q40144028 | The p110alpha isoform of phosphatidylinositol 3-kinase is essential for polyomavirus middle T antigen-mediated transformation |
| Q27851848 | The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis |
| Q35472427 | The p110α isoform of phosphoinositide 3-kinase is essential for cone photoreceptor survival |
| Q34262144 | The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type |
| Q37454384 | The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. |
| Q39853444 | The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1. |
| Q37109616 | Upregulated WDR26 serves as a scaffold to coordinate PI3K/ AKT pathway-driven breast cancer cell growth, migration, and invasion |
| Q96231162 | Virtual docking screening and QSAR studies to explore AKT and mTOR inhibitors acting on PI3K in cancers |
| Q52723996 | p110α of PI3K is necessary and sufficient for quiescence exit in adult muscle satellite cells. |
Search more.